Hereditary transthyretin amyloidosis with polyneuropathy (hATTR-PN), also known as familial amyloid polyneuropathy (FAP), is a rare genetic disease characterized by damage to the peripheral nerves found outside the brain and spinal cord. It is typically…
Problems associated with nerve damage are the main symptoms of hereditary transthyretin amyloidosis with polyneuropathy (hATTR-PN). However, because the disease can affect multiple organs and systems in the body, including the heart, clinical manifestations…
Hereditary transthyretin amyloidosis with polyneuropathy (hATTR-PN) diagnosis typically involves identifying hATTR-PN symptoms and performing specialized testing to confirm the disease’s presence. Inherited mutations in the TTR gene cause hATTR-PN by destabilizing and changing the…
Medications, clinical monitoring, and symptom management can all play a role in hereditary transthyretin amyloidosis with polyneuropathy (hATTR-PN) treatment. Also known as familial amyloid polyneuropathy, hATTR-PN is a genetic condition marked by polyneuropathy, or…
Hereditary transthyretin amyloidosis with polyneuropathy (hATTR-PN), also known as familial amyloid polyneuropathy (FAP), is a form of familial amyloidosis caused by mutations in the TTR gene, which contains instructions for cells to produce a…
Latest News & Community Perspectives
Discussion
People carrying the p.V142I mutation in the TTR gene — which is mostly associated with hereditary transthyretin amyloid cardiomyopathy (hATTR-CM) — often have polyneuropathy, or damage to multiple nerves, a U.S. study shows. But…
Discussion
Researchers have identified a common structure among toxic transthyretin (TTR) clumps, called amyloid fibrils, in heart tissue from people carrying mutations linked to hereditary transthyretin amyloidosis with polyneuropathy (hATTR-PN). Such structural similarity contrasts with…
Discussion
Increased levels of neurofilament light chain (NfL), a marker of nerve damage, are associated with more severe neurological symptoms in people with hereditary transthyretin amyloidosis with polyneuropathy (hATTR-PN), according to a new study from…
Discussion
The injection therapy Wainua (eplontersen) “offers a vital ray of hope” for people living with hereditary transthyretin amyloidosis with polyneuropathy (hATTR-PN), an international team of scientists wrote in a review paper. Available data…
Discussion
People with hereditary transthyretin amyloidosis with polyneuropathy (hATTR-PN) often experience eye-related complications such as eye dryness and floaters in the field of vision, according to a review study. However, available scientific evidence does not…
Discussion
Many adverse-event reports and safety signals linked to Amvuttra (vutrisiran) treatment for hereditary transthyretin amyloidosis with polyneuropathy (hATTR-PN) in real-world databases were consistent with the therapy’s reported safety profile in clinical trials, a…
Discussion
Treatment with Wainua (eplontersen) was associated with slower disease progression and improved quality of life in both men and women with hereditary transthyretin amyloidosis with polyneuropathy (hATTR-PN). That’s according to an exploratory analysis…
Discussion
Carpal tunnel syndrome (CTS) in both wrists may be a red flag of transthyretin amyloidosis (ATTR), including hereditary transthyretin amyloidosis with polyneuropathy (hATTR-PN), a study showed. The researchers also identified imaging abnormalities in the…
Discussion
Amvuttra (vutrisiran) safely and effectively eases symptoms, reduces disability, and improves quality of life in East Asian adults with hereditary transthyretin amyloidosis with polyneuropathy (hATTR-PN), according to a subgroup analysis of the global…
Discussion
Use of the approved therapy Wainua (eplontersen) effectively slows disease progression and improves quality of life among adults with hereditary transthyretin amyloidosis with polyneuropathy (hATTR-PN) — characterized by damage to the peripheral nerves…